ERC-SG-LS6
ERC-SG-LS6
Programme: H2020
90 projects · €134,421,680 total EU contribution (project-level) · 74 participating organizations · 14 countries with participants
Total EU funding
Sum of EC max contribution fields for distinct projects in this topic.
€134,421,680
Countries active
Participant organizations by country (headquarters in CORDIS).
- Germany (21)
- CH (8)
- Italy (7)
- Netherlands (7)
- UK (7)
- Spain (5)
- BE (4)
- France (4)
- PT (3)
- SE (3)
- IL (2)
- AT (1)
- EL (1)
- IE (1)
Open calls
From the EU Funding & Tenders Portal, linked to this topic code when it matches the call identifier. Sync via yarn etl:funding.
No open or forthcoming calls linked to this topic in the database yet.
Top organizations
By number of distinct projects in this topic.
- IP6 projects · FR
- CNRS5 projects · FR
- INSERM5 projects · FR
- HZI3 projects · DE
- INSTITUT CURIE FONDATION3 projects · FR
- KING'S COLLEGE LONDON3 projects · UK
- MPG3 projects · DE
- UNIGE3 projects · CH
- VLAAMS INSTITUUT BIOTECHNOLOGIE FLANDERS INSTITUTE FOR BIOTECHNOLOGY3 projects · BE
- EPFL2 projects · CH
- iMM2 projects · PT
- KI2 projects · SE
Projects
Page 3 of 9
| Project | Programme | EU contribution | Total cost | |
|---|---|---|---|---|
Switch recombination: a model system for DNA editing and repair in human lymphocytes with relevance for primary immunodeficiency and cancer formation IMMUNOSWITCH · 242551 | FP7 | €1,888,166 | €1,888,166 | Details |
Communication between immune cells via release of RNA-carrying vesicles: Lessons from viruses INTERCOM · 337581 | FP7 | €1,499,806 | €1,499,806 | Details |
Identification of Host Determinants for Virus Entry using a Haploid Genetic Approach Viral Host Factors · 309634 | FP7 | €1,495,200 | €1,495,200 | Details |
Pathogen and commensal immunity compared in a reversible infection model that uncouples immunity from pathogen immune evasion REVERSIBLEINFECTION · 281904 | FP7 | €1,499,992 | €1,499,992 | Details |
Innate sensing of HIV and immune responses HIVINNATE · 309848 | FP7 | €1,680,000 | €1,680,000 | Details |
Immune mechanisms of osteopontin-mediated protection in allergic airway disease OPN-IMMUNOREGULATION · 243322 | FP7 | €1,511,200 | €1,511,200 | Details |
Viral frontiers – species barriers of hepatitis C virus replication VIRAFRONT · 281473 | FP7 | €1,444,516 | €1,444,516 | Details |
Closing in on Runx3 and CXCL4 to open novel avenues for therapeutic intervention in systemic sclerosis CIRCUMVENT · 281322 | FP7 | €1,500,000 | €1,500,000 | Details |
Heterotypic Cell Interactions in Hepatitis induced Liver Cancer LIVERMIRCOENV · 281738 | FP7 | €1,499,940 | €1,499,940 | Details |
HOST FACTORS THAT FACILITATE AND RESTRICT HIV-1 REPLICATION HIV HOST FACTORS · 281598 | FP7 | €1,500,000 | €1,500,000 | Details |